Authors retract chemistry paper after failing to get company’s permission to publish

Two chemists who published a paper earlier this year in Bioconjugate Chemistry have withdrawn it, after their company, Life Technologies, let them know they didn’t have permission to submit the work. The retraction notice reads:

Facile Synthesis of Symmetric, Monofunctional Cyanine Dyes for Imaging Applications, by Lai-Qiang Ying and Bruce P. Branchaud, Bioconjugate Chem., 2011, 22 (5), pp 865–869, DOI: 10.1021/bc2001006, has been retracted at the request of the authors and Life Technologies. The article was submitted for publication without the approval of Life Technologies.

Where the paper had appeared previously — it’s been completely removed from the journal’s site, as opposed to being marked as “withdrawn” or “retracted” — this is all that’s left: Continue reading Authors retract chemistry paper after failing to get company’s permission to publish

Physics paper in Science retracted after Vanderbilt facility closes

If the facility you need to reproduce your experiments closes after you’ve discovered questions about your original findings, what do you do?

If you’re a group of physicists that published a 2006 paper in Science, “Desorption of H from Si(111) by Resonant Excitation of the Si-H Vibrational Stretch Mode,” you retract your study. Here’s the notice, from today’s Science: Continue reading Physics paper in Science retracted after Vanderbilt facility closes

You can do that? A massive correction in Nature, but no retraction

courtesy Nature

This past April, Amparo Acker-Palmer and colleagues published a study in Nature, “Ephrin Bs are essential components of the Reelin pathway to regulate neuronal migration.” Within a day of its publication, Nature readers were raising questions about many of its figures. They started like this:

Andy Gu said:

Looks like Fig 1a, the two middle figures are actually the same with little move from desired regions. I don’t trust their data now…..

After several such comments, Nature senior editor Noah Gray weighed in: Continue reading You can do that? A massive correction in Nature, but no retraction

Lack of ethical approval leads to JCO retraction

The Retraction Watch category for “lack of IRB approval” as a reason for retraction — a subject we covered in our most recent Lab Times column — is growing. First there were the 90-odd retractions by Joachim Boldt, then three by Australian researchers studying Aussie-rules football players. Now, we learn that the Journal of Clinical Oncology has retracted a paper over concerns that the authors failed to obtain ethical approval to conduct their study.

The 2010 publication, by researchers at Saitama Medical University in Japan, reported on an analysis of 314 lymphoma patients being treated with chemotherapy — some, and perhaps none, of whom knew they were being studied.

Here’s the notice, which appeared this month: Continue reading Lack of ethical approval leads to JCO retraction

*Savaskan and Nitsch, forced to retract FASEB J paper, correct Cell study with duplicated figure

In August, we wrote about the complicated case of a paper retracted from FASEB Journal that had originally been slated for a correction instead. There had been allegations of misconduct by one of the authors, Nicolai E. Savaskan, and the key parts of the retraction notice for the paper were as follows:

A well-recognized and top-class fact finding commission concluded that the publication contains gross flaws. A key figure (Figure 14) and the conclusions drawn from it could not be underlined with the corresponding primary data.

Savaskan told us at the time that FASEB Journal had agreed to a correction of the figure in question, but ended up retracting the paper after receiving a letter from Annette Gruters-Kieslich at Charite – Universitatsmedizin Berlin, where the work was done. We didn’t get much of an answer from FASEB Journal about why they changed their minds.

*Since understanding why one paper warrants a correction and another gets retracted is important for us at Retraction Watch, a correction of a 2009 Cell paper by a group that included Savaskan and his FASEB J c0-author Robert Nitsch caught our eye. The correction for “Synaptic PRG-1 Modulates Excitatory Transmission via Lipid Phosphate-Mediated Signaling” — a paper cited nine times so far, according to Thomson Scientific’s Web of Knowledge — ran in the September 16, 2011 issue of Cell: Continue reading *Savaskan and Nitsch, forced to retract FASEB J paper, correct Cell study with duplicated figure

Stapel inquiry widens to the University of Groningen, University of Amsterdam

The University of Groningen (UG) has launched an investigation the conduct of Diederik Stapel, the social psychologist accused of fabricating his research.

According to a Google translation of a UG press release: Continue reading Stapel inquiry widens to the University of Groningen, University of Amsterdam

More on Hattori case from co-author: Did grudge lead to scientist’s fall?

We have an update on the case of Yoshiyuki Hattori, the Japanese endocrinologist who has had a half-dozen papers retracted because of issues involving reused data. We’ve reported on some of those retractions, and report on three new ones here.

As a trainee, Hattori spent some time in England, where he met Steven Gross, a prominent pharmacology researcher at Cornell. Gross was impressed with the young physician-scientist, and invited him back to his New York City laboratory to do a postdoc.

Gross’ name appears on one of the retracted articles, “NO suppresses while peroxynitrite sustains NF-κB: a paradigm to rationalize cytoprotective and cytotoxic actions attributed to NO,” which appeared in 2004 in the journal Cardiovascular Research and has been cited 42 times, according to Thomson Scientific’s Web of Knowledge.

According to the notice: Continue reading More on Hattori case from co-author: Did grudge lead to scientist’s fall?

The ‘Goldilocks’ retraction? Revealing differences in how several neurology journals handled related problems

Four neurology journals have retracted articles by a Japanese researcher who admitted to having made “mistakes” in his handling of data. Although the cases are related, the way the journals have handled the  notices is startlingly different. One chose to say nothing, one chose to say little, while two went for full — or at least, approximately that — disclosure.

Guess which ones we like the most? Continue reading The ‘Goldilocks’ retraction? Revealing differences in how several neurology journals handled related problems

Why did Science partially retract the XMRV-chronic fatigue syndrome paper?

If past experience is any indication, billions of pixels will be spilled in the coming days as scientists and advocates debate the latest twist in the story of XMRV, or xenotropic murine leukemia-related virus, and chronic fatigue syndrome (CFS). Today’s news is that Science is partially retracting a 2009 paper by Judy Mikovits and colleagues, including Vincent Lombardi, purporting to show a link between the virus and the syndrome — a paper about which they issued an Expression of Concern in May. The retraction is of a table and a figure — more on that in a bit.

In an excellent blow-by-blow account in Science of the nearly 20-year-long saga, also out today, Jon Cohen and Martin Enserink review the unusual circumstances of that Expression of Concern. Science editor-in-chief Bruce

Alberts and Science Executive Editor Monica Bradford had first suggested that Mikovits and her co-authors retract the paper voluntarily. “Science feels it would be in the best interest of the scientific community,” they wrote in a 26 May letter. Mikovits was livid and questioned Alberts’s motives. “Who wrote that letter? I don’t think it was Science,” she says. The co-authors thought the retraction request was premature, too. “What if we walk away from this based on contamination and it’s not contamination?” Lombardi asked. “You’ve got to give us time to figure this out.”

Alberts stresses that they floated the retraction idea because Science already planned to publish the Expression of Concern. “It wasn’t a public call for retraction,” he notes, emphasizing that the recipients shared it with the media. He also does not think it would have been premature, although he says it’s often a tough call whether to retract a paper. “Ultimately, it requires expert judgment and a lot of sensitivity to the issues,” he says. “We had lost confidence in the results.”

As Science noted in May, two studies accompanied the May Expression of Concern Continue reading Why did Science partially retract the XMRV-chronic fatigue syndrome paper?

Should authors have to retract papers based on data obtained unethically?

via Kent State http://bit.ly/r2CW44

Careful Retraction Watch readers may have noticed that one of the categories in our right-hand column under “by reason for retraction” is “lack of IRB approval.” That’s because in just over a year, we’ve written a number of posts about two cases of retractions for that reason.

One was the now-infamous case of Joachim Boldt, who has retracted some 90 papers. The other was more mundane, about a group studying injuries among Aussie rules football players. 

These retractions — and another case in which lung cancer screening trial investigators have said 90 percent of their consent forms are unobtainable, according to The Cancer Letter and The New York Times — raise some important ethical questions that we explore in our latest LabTimes column. Excerpt: Continue reading Should authors have to retract papers based on data obtained unethically?